Clinical Trial: Cabotegravir & Rilpivirine Antiretroviral Therapy in Pregnancy

U.S., June 11 -- ClinicalTrials.gov registry received information related to the study (NCT07637942) titled 'Cabotegravir & Rilpivirine Antiretroviral Therapy in Pregnancy' on May 27.

Brief Summary: Phase IV, multi-site, open-label, non-randomized study of the pharmacokinetics (PK) of long-acting injectable cabotegravir and rilpivirine (CAB LA + RPV LA) during pregnancy and postpartum.

Study Start Date: July 15

Study Type: OBSERVATIONAL

Condition: HIV -1 Infection

Intervention: DRUG: Every 4-week long-acting injectable cabotegravir and rilpivirine

Long-acting injectable cabotegravir and rilpivirine, initiated pre- or post-conception. Participants will receive these drugs as prescribed outside the study by their non-study clinical ca...